ESGO/ESTRO/ESP宫颈癌患者管理指南——2023年更新
欧洲妇科肿瘤学会(ESGO)联合欧洲放射肿瘤学会(ESTRO)和欧洲病理学会(ESP)对2018年宫颈癌管理循证指南进行更新,新增主题以全面覆盖诊断和治疗相关问题。专家组由欧洲27名专家组成,基于系统检索的新数据经批判性评估,无明确科学证据时依据专业经验和共识判断。指南发布前由155名独立国际执业者和患者代表审阅,涵盖分期、管理、随访、长期生存、生活质量和姑息治疗。
要点
- 指南由ESGO、ESTRO和ESP联合更新,覆盖宫颈癌诊断和治疗所有相关问题。
- 管理包括保留生育功能治疗、早期和局部晚期宫颈癌、简单子宫切除标本发现的浸润性宫颈癌、妊娠期宫颈癌、罕见肿瘤、复发和转移性疾病。
- 指南定义了管理流程以及放疗和病理评估原则。
核心结论
- 更新版指南全面覆盖宫颈癌分期、管理、随访、长期生存、生活质量和姑息治疗,并定义管理流程及放疗和病理评估原则。
研究设计与样本
- ESGO/ESTRO/ESP联合更新2018年循证指南,专家 panel 由欧洲27名专家组成。
- 基于系统检索的新数据经批判性评估,无明确科学证据时依据国际制定组的专业经验和共识判断。
- 指南发布前由155名独立国际执业者和患者代表审阅。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer. Given the large body of new evidence addressing the management of cervical cancer, the three sister societies jointly decided to update these evidence-based guidelines. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment in cervical cancer. To serve on the expert panel (27 experts across Europe) ESGO/ESTRO/ESP nominated practicing clinicians who are involved in managing patients with cervical cancer and have demonstrated leadership through their expertise in clinical care and research, national and international engagement, profile, and dedication to the topics addressed. To ensure the statements were evidence based, new data identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Before publication, the guidelines were reviewed by 155 independent international practitioners in cancer care delivery and patient representatives. These updated guidelines are comprehensive and cover staging, management, follow-up, long-term survivorship, quality of life and palliative care. Management includes fertility sparing treatment, early and locally advanced cervical cancer, invasive cervical cancer diagnosed on a simple hysterectomy specimen, cervical cancer in pregnancy, rare tumors, recurrent and metastatic diseases. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.
引用
- Cibula D, Rosaria Raspollini M, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. Radiother Oncol. 2023. PMID: 37336614. doi:10.1016/j.radonc.2023.109682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。